Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1081-1100 of 1,307 trials

Multifocal Motor Neuropathy: Empasiprubart vs. IVIg

We are studying whether Empasiprubart can improve muscle strength and function in adults with Multifocal Motor Neuropathy compared to standard IVIg treatment.

Multifocal Motor Neuropathy>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Pancreatic and Bile Duct Cancer: 68Ga-FAPI-46 PET Imaging Study

We are testing a new imaging method to better visualize pancreatic and bile duct cancers. This study aims to see how accurately it detects cancer and monitors treatment response.

Cholangiocarcinoma (Bile Duct Cancer)Pancreatic Carcinoma (Pancreatic Cancer)>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Friedreich Ataxia: Vatiquinone Safety Study

We are studying the long-term safety of vatiquinone in patients with Friedreich Ataxia who have previously used this medication. We aim to see how it affects their symptoms over time.

Friedreich's Ataxia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

Nodal T Cell Lymphoma: Duvelisib vs. Gemcitabine or Bendamustine

We are studying whether duvelisib can improve outcomes for patients with relapsed or refractory nodal T cell lymphoma. This trial compares its effects to standard treatments like gemcitabine or bendamustine.

Refractory Adult T-cell LymphomaRelapsed/Refractory Nodal T Cell Lymphoma with TFH Phenotype>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Kidney Transplant in Children: Prolonged-Release Tacrolimus Study

We are studying a new form of tacrolimus for children who have undergone kidney transplantation. The goal is to see if it works as well and is as safe as the current version used.

Caucasian Pediatric Kidney Transplant Recipients1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesNephrologyPediatrics

Primary Sjögren's Disease: Efgartigimod Treatment Study

We are testing a new medication, efgartigimod, for adults with Primary Sjögren's Disease to see if it helps reduce disease activity and improve symptoms compared to a placebo.

Sjögren's Syndrome>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Acromegaly: Debio 4126 Treatment Study

We are testing a new formulation of Debio 4126 in patients with acromegaly who have been treated with other medications. The study aims to see if it helps maintain normal hormone levels and evaluates its safety compared to a placebo.

Acromegaly1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementEndocrinology

Gastric Cancer: HLX22 Treatment Study

We are studying a new drug, HLX22, combined with standard treatments for patients with advanced gastric cancer. The goal is to see if it works better and is safe compared to existing treatment options.

Gastric Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementGastroenterologyOncology

Cardiovascular Health in Type 2 Diabetes: COLCOT-T2D Study

We are studying whether colchicine and non-enteric coated aspirin can improve heart health in high-risk adults with type 2 diabetes. The goal is to see if these treatments can reduce serious heart-related events.

Unspecified Cardiovascular DiseaseConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyEndocrinology

Pain Medication Tapering for Persistent Spinal Pain

We are studying how different methods of reducing pain medication affect disability in patients with Persistent Spinal Pain Syndrome Type II after spinal cord stimulation. This research may help improve pain management strategies.

Persistent Spinal Pain Syndrome Type II1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurologyOrthopedics and Traumatology

Ovarian Cancer: NIraparib and Dostarlimab Study

We are testing a new treatment combination for patients with recurrent ovarian cancer who cannot have platinum therapy. The study aims to see if this combination helps patients live longer compared to standard chemotherapy.

Recurrent Ovarian CancerConfirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Atherosclerotic Cardiovascular Disease: Maridebart Cafraglutide

We are studying whether maridebart cafraglutide can improve heart health in people with atherosclerotic cardiovascular disease who are overweight or obese. This trial compares its effects to a placebo alongside standard care.

Arteriosclerotic Cardiovascular DiseaseConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Maridebart Cafraglutide for Heart Failure and Obesity

We are studying whether maridebart cafraglutide can improve heart failure symptoms and reduce hospital visits for people with heart failure and obesity. This trial compares the new treatment to a placebo alongside standard care.

Heart FailureConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

ALS Treatment: Masitinib with Riluzole

We are studying whether adding masitinib to Riluzole helps improve outcomes for people with Amyotrophic Lateral Sclerosis. This trial will assess its safety and effectiveness compared to a placebo.

Amyotrophic Lateral Sclerosis6-12 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesInternal MedicineNeurology

Multiple Sclerosis: Masitinib Treatment Study

We are investigating whether the oral medication masitinib is effective and safe for people with primary or secondary progressive multiple sclerosis without relapses. This study compares masitinib to a placebo to evaluate its impact on various symptoms and overall health.

Multiple Sclerosis1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteNeurology

Granulomatosis with Polyangiitis: New Salvage Therapies

We are testing different treatment combinations for patients who haven't responded to standard care for granulomatosis with polyangiitis. The goal is to find the most effective way to help induce remission and improve overall health.

Granulomatosis with Polyangiitis (GPA)1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Rheumatoid Arthritis: Targeted Therapy vs. Triple Therapy

We are studying whether targeted therapies are more effective than a combination of three other medications for patients with rheumatoid arthritis who haven't responded to standard treatments. The trial also looks at safety and quality of life.

Rheumatoid ArthritisConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

COPD: Atorvastatin for Reducing Exacerbations

We are studying whether atorvastatin can help reduce flare-ups in smokers with chronic obstructive pulmonary disease. The trial also looks at how this medication may affect lung function and quality of life.

Chronic Obstructive Pulmonary Disease>2 yearsConfirmation phase (III)Standard MedicinesInternal MedicinePulmonology

Preventing Infections in ICU Patients with Interferon Gamma

We are studying whether interferon gamma can help prevent secondary infections in ICU patients with weakened immune systems. This research may improve recovery and reduce hospital stays.

Sustained Immunosuppression>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteInfectious DiseasesInternal MedicinePulmonology

Chronic Rhinosinusitis with Nasal Polyps: Itepekimab Study

We are investigating whether itepekimab can help adults with chronic rhinosinusitis and nasal polyps by reducing polyp size and nasal congestion. This study will also look at its effects on overall symptoms and quality of life.

Chronic Rhinosinusitis with Nasal PolypsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOtolaryngologyPulmonology